Stock on Watch: Regeneron Pharmaceuticals, Inc. (REGN)

Company Profile:

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. It invents life-transforming medicines for people with serious diseases and is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and numerous product candidates in development. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Recent News:

The company reported, that first quarter 2018 GAAP net income per diluted share increased by 93% to $4.16 versus first quarter 2017 and first quarter 2018 non-GAAP net income per diluted share increased 60% to $4.67 versus first quarter 2017.

On March 21, 2018, Regeneron Pharmaceuticals, Inc. (REGN) and Alnylam Pharmaceuticals, Inc. (ALNY) announced a collaboration to identify RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis (NASH) and potentially other related diseases.


Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.


Profitability – Measures the historical price movement of the stock.


Solvency – Measures the solvency of the company based on several ratios.


Efficiency – Measures the strength and historic growth of a company’s return on invested capital.



REGN’s strengths can be seen in its better growth and strong profitablity compared with its peers. Its revenue and net income have increased over recent several years. Technical indicators signal the bullish signs, as there is a bullish crossover in Stochastic Oscillator. The RSI is strong in the bullish zone and the MACD is trying to cross back up. We rate Regeneron Pharmaceuticals, Inc. (REGN) a STRONG BUY.

About the Author

has written 10757 stories on this site.

Copyright © 2012 Nine Stocks